EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Somatic inactivation of breast cancer predisposition genes in tumors associated with pathogenic germline variants

Belle W X Lim iD, Na Li iD, Sakshi Mahale, Simone McInerny, Magnus Zethoven iD, Simone M Rowley, Joanne Huynh, Theresa Wang, Jue Er Amanda Lee, Mia Friedman, Lisa Devereux, Rodney J Scott und 3 weitere

JNCI: Journal of the National Cancer Institute · 08.02.2023 · 115 (2) · 181-189

DOI: 10.1093/jnci/djac196 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 31.10.2022. Verfasst von Belle W X Lim und 14 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Breast Neoplasms, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: EPA, National Breast Cancer Foundation, Victorian Cancer Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Breast cancers (BCs) that arise in individuals heterozygous for a germline pathogenic variant in a susceptibility gene, such as BRCA1 and BRCA2, PALB2, and RAD51C, have been shown to exhibit biallelic loss in the respective genes and be associated with triple-negative breast cancer (TNBC) and distinctive somatic mutational signatures. Tumor sequencing thus presents an orthogonal approach to assess the role of candidate genes in BC development.

Methods

Exome sequencing was performed on paired normal-breast tumor DNA from 124 carriers of germline loss-of-function (LoF) or missense variant carriers in 15 known and candidate BC predisposition genes identified in the BEACCON case-control study. Biallelic inactivation and association with tumor genome features including mutational signatures and homologous recombination deficiency (HRD) score were investigated.

Results

BARD1-carrying TNBC (4 of 5) displayed biallelic loss and associated high HRD scores and mutational signature 3, as did a RAD51D-carrying TNBC and ovarian cancer. Biallelic loss was less frequent in BRIP1 BCs (4 of 13) and had low HRD scores. In contrast to other established BC genes, BCs from carriers of CHEK2 LoF (6 of 17) or missense (2 of 20) variant had low rates of biallelic loss. Exploratory analysis of BC from carriers of LoF variants in candidate genes such as BLM, FANCM, PARP2, and RAD50 found little evidence of biallelic inactivation.

Conclusions

BARD1 and RAD51D behave as classic BRCA-like predisposition genes with biallelic inactivation, but this was not observed for any of the candidate genes. However, as demonstrated for CHEK2, the absence of biallelic inactivation does not provide definitive evidence against the gene’s involvement in BC predisposition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsTriple Negative Breast NeoplasmsFemaleHumansCase-Control StudiesGenetic Predisposition to DiseaseGerm-Line MutationGenes, BRCA2DNA Helicases

Substanzen

FANCM protein, humanDNA Helicases

Autor:innen und Institutionen

  • Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia.
  • Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
  • Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia.
  • Bioinformatics Core Facility, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Molecular Genomics Core, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

ORCID-Profile: Belle W X Lim, Na Li, Magnus Zethoven, Ian G Campbell

Förderung

  • EPA
  • National Breast Cancer Foundation
  • Victorian Cancer Agency
  • National Health and Medical Research Council of Australia
  • Cancer Australia
  • National Health and Medical Research Council
  • Cancer Council Victoria Grants-in-Aid
  • Cancer Council Victoria

Zitieren

APA

Lim, B. W. X., Li, N., Mahale, S., McInerny, S., Zethoven, M., Rowley, S. M., Huynh, J., Wang, T., Lee, J. E. A., Friedman, M., Devereux, L., Scott, R. J., Sloan, E. K., James, P. A., & Campbell, I. G. (2023). Somatic inactivation of breast cancer predisposition genes in tumors associated with pathogenic germline variants. JNCI: Journal of the National Cancer Institute, 115(2), 181-189. https://doi.org/10.1093/jnci/djac196

Vancouver

Lim BWX, Li N, Mahale S, McInerny S, Zethoven M, Rowley SM, et al. Somatic inactivation of breast cancer predisposition genes in tumors associated with pathogenic germline variants. JNCI: Journal of the National Cancer Institute. 2023;115(2):181-189. doi:10.1093/jnci/djac196

BibTeX
@article{Lim2023,
  author = {Lim, Belle W X and Li, Na and Mahale, Sakshi and McInerny, Simone and Zethoven, Magnus and Rowley, Simone M and Huynh, Joanne and Wang, Theresa and Lee, Jue Er Amanda and Friedman, Mia and Devereux, Lisa and Scott, Rodney J and Sloan, Erica K and James, Paul A and Campbell, Ian G},
  title = {Somatic inactivation of breast cancer predisposition genes in tumors associated with pathogenic germline variants},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2023},
  volume = {115},
  number = {2},
  pages = {181--189},
  doi = {10.1093/jnci/djac196}
}
Kostenlos starten →